Hospital
Castleview Hospital LLC
Castleview Hospital LLC was paid $6.00M by Medicaid between Jan 2018 and Dec 2024, across 148 billing codes. Its largest line is 8888888, Internal/system code - not a standard HCPCS code — 38% of everything it billed.
33Billing provider infoCASTLEVIEW HOSPITAL LLC
PRICE, UT 84501
PRICE, UT 84501
33aNPI1417064205assigned 08/25/2006
33bProvider typeRural Acute Care Hospital
28Total paid$6.00M
24GClaims183,814
24DCodes billed148
24AFirst – last monthJan 2018 – Dec 2024
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official LAWRENCE, CHARLOTTE controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 29,616 | $686K | |
| 2019 | 30,910 | $837K | |
| 2020 | 27,891 | $897K | |
| 2021 | 40,789 | $1.37M | |
| 2022 | 41,639 | $1.53M | |
| 2023 | 6,982 | $243K | |
| 2024incomplete | 5,987 | $436K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 8888888 | Internal/system code - not a standard HCPCS code | 38% | 2,290 | 1,352 | $2.26M |
| J7120 | Ringers lactate infusion, up to 1000 cc | 9.5% | 2,947 | 2,665 | $572K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 7.6% | 9,865 | 8,489 | $457K |
| 80053 | Comprehensive metabolic panel | 5.4% | 14,329 | 11,748 | $324K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 4.4% | 4,045 | 3,673 | $263K |
| 36415 | Collection of venous blood by venipuncture | 3.9% | 3,155 | 2,811 | $236K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 3.9% | 8,054 | 7,282 | $236K |
| J7030 | Infusion, normal saline solution , 1000 cc | 3.5% | 3,001 | 2,624 | $212K |
| J7050 | Infusion, normal saline solution, 250 cc | 2.8% | 3,968 | 3,451 | $169K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.7% | 1,659 | 1,571 | $160K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.7% | 1,686 | 1,553 | $103K |
| 71046 | Radiologic examination, chest; 2 views | 1.5% | 2,466 | 2,294 | $92K |
136 more codes
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.4% | 3,695 | $86K |
| 81001 | 1.4% | 7,041 | $84K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 1.1% | 3,532 | $65K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 4,417 | $43K |
| 99285 | Emergency room visit (most serious) | <1% | 3,676 | $40K |
| 71045 | Radiologic examination, chest; single view | <1% | 1,963 | $31K |
| 87088 | <1% | 2,429 | $30K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,092 | $30K |
| 87275 | <1% | 819 | $30K | |
| 87631 | <1% | 314 | $23K | |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 317 | $22K |
| 73610 | <1% | 205 | $20K | |
| 86140 | <1% | 6,257 | $19K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,539 | $18K |
| 76830 | Ultrasound, transvaginal | <1% | 119 | $17K |
| 87077 | <1% | 1,159 | $16K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 499 | $14K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 185 | $13K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,052 | $13K |
| 73630 | <1% | 271 | $13K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,558 | $12K |
| 85610 | <1% | 1,813 | $12K | |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 67 | $12K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 585 | $12K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 2,784 | $11K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 328 | $10K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 1,979 | $10K |
| 73562 | <1% | 156 | $10K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 38 | $9K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,434 | $8K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 71 | $8K |
| 84439 | <1% | 1,208 | $8K | |
| 73110 | <1% | 79 | $8K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 121 | $8K |
| 87070 | <1% | 200 | $7K | |
| 80061 | Lipid panel | <1% | 978 | $7K |
| 73030 | <1% | 90 | $7K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 15,882 | $7K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 239 | $7K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 4,364 | $6K |
| 73130 | <1% | 122 | $6K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 106 | $6K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 248 | $5K |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 1,600 | $5K |
| 86850 | <1% | 277 | $5K | |
| 82962 | <1% | 1,017 | $5K | |
| 84484 | <1% | 2,679 | $5K | |
| 74018 | <1% | 125 | $5K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 51 | $5K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 2,932 | $4K |
| 87420 | <1% | 234 | $4K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 810 | $3K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 2,220 | $3K |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 67 | $3K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 565 | $3K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 225 | $3K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 297 | $3K |
| 85379 | <1% | 1,095 | $2K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 118 | $2K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 820 | $2K |
| 84702 | <1% | 208 | $2K | |
| 80055 | <1% | 26 | $2K | |
| G0378 | Hospital observation service, per hour | <1% | 1,014 | $2K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 107 | $2K |
| 93971 | <1% | 41 | $2K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 72 | $2K |
| 81025 | <1% | 1,369 | $2K | |
| 83690 | <1% | 2,670 | $1K | |
| 85027 | <1% | 1,154 | $1K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 280 | $1K |
| 84703 | <1% | 960 | $1K | |
| 83880 | <1% | 866 | $1K | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 618 | $1K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 3,813 | $1K |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 275 | $1K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 128 | $961.80 |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 670 | $920.55 |
| 87081 | <1% | 45 | $915.38 | |
| 82247 | <1% | 132 | $910.93 | |
| 80074 | <1% | 60 | $853.29 | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 2,150 | $828.47 |
| 70486 | <1% | 12 | $804.96 | |
| 86592 | <1% | 27 | $757.03 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 515 | $656.62 |
| 85007 | <1% | 289 | $615.39 | |
| 87040 | <1% | 1,133 | $605.69 | |
| 86803 | <1% | 29 | $533.69 | |
| 86703 | <1% | 265 | $401.24 | |
| 83540 | <1% | 262 | $346.87 | |
| 82728 | <1% | 55 | $335.36 | |
| 83605 | <1% | 1,402 | $327.67 | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 394 | $310.26 |
| 86900 | <1% | 481 | $260.61 | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 157 | $237.75 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,288 | $221.82 |
| 84403 | <1% | 14 | $181.01 | |
| 82950 | <1% | 12 | $154.52 | |
| 73502 | <1% | 14 | $142.97 | |
| 82607 | <1% | 34 | $129.39 | |
| 87276 | <1% | 819 | $114.41 | |
| 85652 | <1% | 886 | $95.20 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 614 | $91.75 |
| 82550 | <1% | 148 | $83.87 | |
| 82150 | <1% | 119 | $68.33 | |
| 83735 | <1% | 912 | $62.35 | |
| 82565 | <1% | 52 | $60.92 | |
| 88304 | <1% | 75 | $51.05 | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 33 | $47.77 |
| 85730 | <1% | 698 | $23.80 | |
| 87186 | <1% | 1,122 | $23.79 | |
| 86677 | <1% | 57 | $12.95 | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 42 | $0.00 |
| 82977 | 0% | 44 | $0.00 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 0% | 47 | $0.00 |
| 87653 | 0% | 43 | $0.00 | |
| Q0244 | Injection, casirivimab and imdevimab, 1200 mg | 0% | 25 | $0.00 |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 0% | 15 | $0.00 |
| 94761 | 0% | 92 | $0.00 | |
| J2704 | Injection, propofol, 10 mg | 0% | 1,954 | $0.00 |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 0% | 183 | $0.00 |
| 86901 | 0% | 467 | $0.00 | |
| A9270 | Non-covered item or service | 0% | 246 | $0.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 85 | $0.00 |
| 83550 | 0% | 145 | $0.00 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 587 | $0.00 |
| J2060 | Injection, lorazepam, 2 mg | 0% | 12 | $0.00 |
| 96376 | 0% | 419 | $0.00 | |
| 82746 | 0% | 16 | $0.00 | |
| 82553 | 0% | 45 | $0.00 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 0% | 33 | $0.00 |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | 0% | 13 | $0.00 |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | 0% | 45 | $0.00 |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | 0% | 15 | $0.00 |
| J8540 | Dexamethasone, oral, 0.25 mg | 0% | 12 | $0.00 |
| 97162 | 0% | 12 | $0.00 | |
| J1630 | Injection, haloperidol, up to 5 mg | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLAWRENCE, CHARLOTTE (SECRETARY)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.